TODY: Tongue Dysbiosis Effects on Arterial Pressure of Periodontitis Patients

Sponsor
University of Taubate (Other)
Overall Status
Unknown status
CT.gov ID
NCT04027179
Collaborator
Conselho Nacional de Desenvolvimento Científico e Tecnológico (Other)
90
1
3
23
3.9

Study Details

Study Description

Brief Summary

Blood pressure control is crucial for individuals' wellbeing. However, many daily aspects such as diet could impair blood pressure control. In addition, many people living under different conditions in different countries are affected by some kind of gum disease. These people experience gingival bleeding, bad breath, teeth mobility and pain. Throughout gum disease development the number of oral germs in the mouth increases including their levels in tongue surface. Oral bacterial are able to convert nitrate widely found in food in nitrite which influences blood pressure. Frequently treatment of gum diseases general combines manual instrumentation with mouthwashes. However, it has been suggested that reduction of oral bacteria by mouthwashes, especially chlorhexidine, is accompanied by decreased conversion of nitrate to nitrite and that this minor nitrite availability would increase blood pressure. Therefore, this is a point to be clarified for patients, physicians and dentists.

This study will investigate the relation between treatment with mouthwashes and blood pressure of patients with destructive gum disease based on nitrite levels in saliva, bacterial levels in tongue and values of arterial blood pressure which will be monitored over 6 months. In addition, usual clinical parameters and alteration of oral cells' DNA will be also monitored overtime. Patients will be treated under local anesthesia and manual instrumentation within 24 hours. They will receive oral care products too. There will be 3 treatment groups (manual instrumentation + chlorhexidine mouthwash [2 times a day for 3 weeks], manual instrumentation + placebo mouthwash [2 times a day for 3 weeks] and manual instrumentation + no mouthwash) and 2 dental appointments before treatment. After treatment, patients will be examined at 7, 14, 21, 90 and 180 days. Saliva, plaque and cell sampling will be fast and by no invasive methods.

Condition or Disease Intervention/Treatment Phase
  • Drug: 0.12% chlorhexidine digluconate mouthwash
  • Procedure: Periodontal instrumentation
  • Drug: Placebo mouthwash
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Tongue Bacterial Dysbiosis Related to Periodontal Therapy on Arterial Pressure Control Based on Salivary Nitrite Availability: a Periodontitis Patients Randomized Controlled Clinical Trial
Anticipated Study Start Date :
Aug 1, 2020
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: FMS chlorhexidine mouthwash

Full-mouth scaling and root planning with manual curettes, 20 ml of 0.12% chlorhexidine gluconate mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with 0.12% chlorhexidine gluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).

Drug: 0.12% chlorhexidine digluconate mouthwash
0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).

Procedure: Periodontal instrumentation
Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.

Placebo Comparator: FMS placebo mouthwash

Full-mouth scaling and root planning with manual curettes, 20 ml of placebo mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).

Procedure: Periodontal instrumentation
Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.

Drug: Placebo mouthwash
placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).

Active Comparator: FMS no mouthwash

Full-mouth scaling and root planning with manual curettes.

Procedure: Periodontal instrumentation
Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.

Outcome Measures

Primary Outcome Measures

  1. Efficacy - comparative tongue bacterial counts [Baseline and 3 months]

    Changes of Veillonella, Streptococcus, Neisseria, Fusobacterium and Acytinomyces counts in samples from tongue dorsal

Secondary Outcome Measures

  1. Safety - comparative nitrite levels in saliva [Baseline and 3 months]

    Differences in mean nitrite levels from saliva samples pre- and post-treatment

  2. Safety - Percentage of hypertension episodes [Baseline and 3 months]

    Changes in the percentage of hypertension episode

  3. Safety - status of DNA methylation in oral cells [Baseline and 3 months]

    Mean changes of DNA methylation statuses in oral cells

  4. Efficacy - Percentage of periodontal pockets [Baseline and 6 months]

    Changes in the percentage of deep periodontal pockets

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 12 natural teeth; chronic periodontitis stages II and III; no systemic medication; non smokers; normal blood pressure; no mouthwash regular use; antibiotics > 3 months prior to study; dental treatment > 3 months prior to study.
Exclusion Criteria:
  • known alergy to chlorhexidine; removable prosthodontics apparatus; pregnant and breast feeding women.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Taubate - Nucleus of periodontal research Taubate SP Brazil 12020330

Sponsors and Collaborators

  • University of Taubate
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Taubate
ClinicalTrials.gov Identifier:
NCT04027179
Other Study ID Numbers:
  • CAAE17482019.5.0000.5501
First Posted:
Jul 19, 2019
Last Update Posted:
Jul 23, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 23, 2019